Sex: U
Vaccine: COVID19
Symptoms: COVID-19 immunisation, Interchange of vaccine products, Measles, Pneumonia
Clinical narrative: Measles; Pneumonia; revaccination with different COVID-19 vaccine; Interchange of vaccine products; This spontaneous case was reported by a patient and describes the occurrence of MEASLES (Measles) and PNEUMONIA (Pneumonia) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Previously administered products included for Product used for unknown indication: Covid (pfizer)vaccines (Patient had three Pfizer vaccines.), VARICELLA ZOSTER VACCINE, Flu shot vaccine (have not missed a flu shot since 1974), POLIO VACCINE (Patient had all three forms of the polio vaccine and back in the 50s). Past adverse reactions to the above products included No adverse event with Covid (pfizer)vaccines, Flu shot vaccine, POLIO VACCINE and VARICELLA ZOSTER VACCINE.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced MEASLES (Measles) (seriousness criterion medically significant), PNEUMONIA (Pneumonia) (seriousness criterion medically significant), COVID-19 IMMUNISATION (revaccination with different COVID-19 vaccine) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). At the time of the report, MEASLES (Measles) and PNEUMONIA (Pneumonia) outcome was unknown and COVID-19 IMMUNISATION (revaccination with different COVID-19 vaccine) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) had resolved.            No concomitant medication information was reported.  No treatment medication information was reported.  Company comment:  This spontaneous case report concerns a patient of an unknown age and gender, with no medical history provided, who experienced serious (medically significant) unexpected events of Pneumonia and Measles which occurred after the patient had received the mRNA-1273.222 vaccine (as fourth vaccination for COVID-19 immunisation). The patient previously had received three doses of Pfizer COVID-19 vaccine. It was stated that after vaccination with the mRNA-1273.222 the patient developed measles and pneumonia. At the time of this report, the outcome of these events was unknown and no additional details regarding clinical course of these events were provided. Having in mind that the patient had received Pfizer COVID-19 vaccine prior to vaccination with the mRNA-1273.222 vaccine, Interchange of vaccine products and COVID-19 immunisation (revaccination with different COVID-19 vaccine) are also considered in this specific case report. No further details were available for medical assessment. The benefit-risk relationship of mRNA-1273.222 vaccine is not affected by this report.; Sender's Comments: This spontaneous case report concerns a patient of an unknown age and gender, with no medical history provided, who experienced serious (medically significant) unexpected events of Pneumonia and Measles which occurred after the patient had received the mRNA-1273.222 vaccine (as fourth vaccination for COVID-19 immunisation). The patient previously had received three doses of Pfizer COVID-19 vaccine. It was stated that after vaccination with the mRNA-1273.222 the patient developed measles and pneumonia. At the time of this report, the outcome of these events was unknown and no additional details regarding clinical course of these events were provided. Having in mind that the patient had received Pfizer COVID-19 vaccine prior to vaccination with the mRNA-1273.222 vaccine, Interchange of vaccine products and COVID-19 immunisation (revaccination with different COVID-19 vaccine) are also considered in this specific case report. No further details were available for medical assessment. The benefit-risk relationship of mRNA-1273.222 vaccine is not affected by this report.